
EyePoint Pharmaceuticals (EYPT) Stock Forecast & Price Target
EyePoint Pharmaceuticals (EYPT) Analyst Ratings
Bulls say
EyePoint Pharmaceuticals has shown significant progress in its development and commercialization of ophthalmic products, particularly with its recent positive topline results from the Phase 2 VERONA trial of DURAVYU 2.7 mg, which demonstrated substantial improvements in visual acuity and anatomical control. Despite an increase in General and Administrative (G&A) expenses to $52.4 million and Research and Development (R&D) expenses to $132.9 million, the focus on advancing its innovative Durasert E and Verisome technology platforms suggests a commitment to long-term growth and market positioning. Additionally, the company’s geographic expansion across the U.S., China, and the UK, coupled with the recent FDA approvals, indicates a robust foundation for revenue growth and enhanced product offerings in the ophthalmic market.
Bears say
EyePoint Pharmaceuticals has experienced a notable decline in the improvement of best-corrected visual acuity (BCVA) among patients in the high-dose Duravyu cohort between Week 20 and Week 24, indicating potential efficacy concerns. Management acknowledged this drop-off but cited an individual patient’s missed appointment and treatment as an outlier, which raises questions about the overall consistency of treatment results. Furthermore, downward revisions to risk-adjusted projections and price targets have been indicated, reflecting heightened uncertainty regarding the company’s financial outlook.
This aggregate rating is based on analysts' research of EyePoint Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
EyePoint Pharmaceuticals (EYPT) Analyst Forecast & Price Prediction
Start investing in EyePoint Pharmaceuticals (EYPT)
Order type
Buy in
Order amount
Est. shares
0 shares